William Blair Issues Optimistic Forecast for ABT Earnings

Abbott Laboratories (NYSE:ABT - Free Report) - Investment analysts at William Blair upped their Q3 2025 earnings per share estimates for shares of Abbott Laboratories in a report released on Thursday, October 17th. William Blair analyst M. Kaczor now forecasts that the healthcare product maker will post earnings of $1.32 per share for the quarter, up from their previous estimate of $1.31. The consensus estimate for Abbott Laboratories' current full-year earnings is $4.66 per share.

A number of other research firms also recently weighed in on ABT. Mizuho lifted their target price on Abbott Laboratories from $115.00 to $130.00 and gave the stock a "neutral" rating in a research report on Thursday. Citigroup boosted their price objective on Abbott Laboratories from $119.00 to $127.00 and gave the company a "buy" rating in a research report on Thursday, August 22nd. Piper Sandler raised their target price on Abbott Laboratories from $131.00 to $133.00 and gave the stock an "overweight" rating in a research report on Thursday. Piper Sandler Companies assumed coverage on shares of Abbott Laboratories in a report on Thursday, September 19th. They issued an "overweight" rating and a $131.00 price target on the stock. Finally, Jefferies Financial Group raised their price objective on shares of Abbott Laboratories from $120.00 to $125.00 and gave the stock a "hold" rating in a report on Thursday. Four investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $129.67.

Abbott Laboratories Stock Performance

NYSE ABT traded down $2.40 during midday trading on Monday, hitting $116.99. The company had a trading volume of 7,698,024 shares, compared to its average volume of 5,744,756. The firm has a fifty day simple moving average of $113.97 and a two-hundred day simple moving average of $108.48. The stock has a market cap of $203.52 billion, a price-to-earnings ratio of 36.55, a P/E/G ratio of 2.74 and a beta of 0.72. The company has a quick ratio of 1.18, a current ratio of 1.68 and a debt-to-equity ratio of 0.33. Abbott Laboratories has a fifty-two week low of $91.64 and a fifty-two week high of $121.64.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings results on Wednesday, October 16th. The healthcare product maker reported $1.21 EPS for the quarter, topping analysts' consensus estimates of $1.20 by $0.01. The company had revenue of $10.64 billion during the quarter, compared to analyst estimates of $10.55 billion. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.65%. The company's quarterly revenue was up 4.9% compared to the same quarter last year. During the same period in the previous year, the company earned $1.14 earnings per share.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 15th. Stockholders of record on Tuesday, October 15th will be issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 1.88%. The ex-dividend date of this dividend is Tuesday, October 15th. Abbott Laboratories's payout ratio is presently 68.54%.

Insider Activity

In related news, CEO Robert B. Ford sold 141,679 shares of the company's stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $116.41, for a total transaction of $16,492,852.39. Following the transaction, the chief executive officer now owns 220,059 shares in the company, valued at $25,617,068.19. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ABT. Townsend Asset Management Corp NC ADV bought a new position in shares of Abbott Laboratories in the 3rd quarter valued at about $206,000. Copeland Capital Management LLC acquired a new position in Abbott Laboratories in the third quarter valued at approximately $142,000. Whittier Trust Co. of Nevada Inc. grew its holdings in Abbott Laboratories by 0.9% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 181,160 shares of the healthcare product maker's stock worth $20,654,000 after acquiring an additional 1,605 shares during the period. Whittier Trust Co. raised its position in shares of Abbott Laboratories by 0.6% during the 3rd quarter. Whittier Trust Co. now owns 382,513 shares of the healthcare product maker's stock valued at $43,610,000 after acquiring an additional 2,315 shares during the last quarter. Finally, Northwest Investment Counselors LLC lifted its stake in shares of Abbott Laboratories by 0.8% in the 3rd quarter. Northwest Investment Counselors LLC now owns 23,019 shares of the healthcare product maker's stock valued at $2,624,000 after purchasing an additional 181 shares during the period. Institutional investors and hedge funds own 75.18% of the company's stock.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.